BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33563892)

  • 21. Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations.
    Tetzlaff MT; Curry JL; Ning J; Sagiv O; Kandl TL; Peng B; Bell D; Routbort M; Hudgens CW; Ivan D; Kim TB; Chen K; Eterovic AK; Shaw K; Prieto VG; Yemelyanova A; Esmaeli B
    Clin Cancer Res; 2019 Feb; 25(4):1280-1290. PubMed ID: 30420449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic alterations of GI-NECs involving three main signaling pathways.
    Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
    Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
    Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Grading of Neuroendocrine Carcinomas: Correlation of
    Liverani C; Bongiovanni A; Mercatali L; Foca F; Pieri F; De Vita A; Spadazzi C; Miserocchi G; Recine F; Riva N; Nicolini S; Severi S; Martinelli G; Ibrahim T
    Dis Markers; 2018; 2018():6878409. PubMed ID: 30627226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
    Wang B; Yao J; Ma R; Liu D; Lu Y; Shi G; An L; Xia A; Chen F; Pang S; Zhai X; Liu G; Chen S; Xu M; Song L; Xu H
    Int J Cancer; 2021 Apr; 148(8):2036-2047. PubMed ID: 33403690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
    Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
    Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine Carcinomas of the Gallbladder: A Clinicopathologic and Immunohistochemical Analysis of 34 Resected Cases.
    Lee SM; Sung CO
    Am J Surg Pathol; 2020 Oct; 44(10):1308-1321. PubMed ID: 32739935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unraveling Neuroendocrine Gallbladder Cancer: Comprehensive Clinicopathologic and Molecular Characterization.
    de Bitter TJJ; Kroeze LI; de Reuver PR; van Vliet S; Vink-Börger E; von Rhein D; Jansen EAM; Nagtegaal ID; Ligtenberg MJL; van der Post RS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.
    Kamboj M; Gandhi JS; Gupta G; Sharma A; Pasricha S; Mehta A; Chandragouda D; Sinha R
    J Gastrointest Cancer; 2015 Dec; 46(4):356-64. PubMed ID: 26208508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gallbladder Mixed Neuroendocrine-Non-neuroendocrine Neoplasm (MiNEN) Arising in Intracholecystic Papillary Neoplasm: Clinicopathologic and Molecular Analysis of a Case and Review of the Literature.
    Sciarra A; Missiaglia E; Trimech M; Melloul E; Brouland JP; Sempoux C; La Rosa S
    Endocr Pathol; 2020 Mar; 31(1):84-93. PubMed ID: 31981075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
    Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
    Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention.
    Giraldo NA; Drill E; Satravada BA; Dika IE; Brannon AR; Dermawan J; Mohanty A; Ozcan K; Chakravarty D; Benayed R; Vakiani E; Abou-Alfa GK; Kundra R; Schultz N; Li BT; Berger MF; Harding JJ; Ladanyi M; O'Reilly EM; Jarnagin W; Vanderbilt C; Basturk O; Arcila ME
    Clin Cancer Res; 2022 Dec; 28(24):5359-5367. PubMed ID: 36228155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.
    Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
    Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
    [No Abstract]   [Full Text] [Related]  

  • 37. NGS Analysis Confirms Common
    Peterson C; Moore R; Hicks JL; Morsberger LA; De Marzo AM; Zou Y; Eberhart CG; Campbell AA
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline
    Kovac M; Woolley C; Ribi S; Blattmann C; Roth E; Morini M; Kovacova M; Ameline B; Kulozik A; Bielack S; Hartmann W; Ballinger ML; Thomas DM; Tomlinson I; Nathrath M; Heinimann K; Baumhoer D
    J Med Genet; 2021 Jan; 58(1):20-24. PubMed ID: 32179705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma.
    Iijima M; Yokobori T; Mogi A; Shimizu K; Yajima T; Kosaka T; Ohtaki Y; Obayashi K; Nakazawa S; Gombodorj N; Tsukagoshi M; Shirabe K; Kuwano H
    Ann Surg Oncol; 2019 Jun; 26(6):1744-1750. PubMed ID: 30924018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.